Filovirus Infections

Tropical Infectious Diseases

Volumn , Issue , 2011, Pages 483-491

  Wahl Jensen, Victoria ^a   Peters, C J ^b   Jahrling, Peter B ^a   Feldmann, Heinz ^c   Kuhn, Jens H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878341248     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7020-3935-5.00073-2     Document Type: Chapter

References (186)

1. Kuhn JH Filoviruses: A Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies 2008, Springer, Vienna.
2. Sanchez A, Geisbert TW, Feldmann H Filoviridae: Marburg and Ebola viruses. Fields Virology 2007, 1409. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA. 5th ed. B.N. Fields (Ed.).
3. Feldmann H, Geisbert TW, Jahrling PB, et al. Family Filoviridae. Virus Taxonomy - Eighth Report of the International Committee on Taxonomy of Viruses 2005, 645. Elsevier/Academic Press. C.M. Fauquet (Ed.).
4. Sanchez A, Khan AS, Zaki SR, et al. Filoviridae: Marburg and Ebola viruses. Fields' Virology 2001, 1279. Williams & Wilkins, Philadelphia, PA: Lippincott. 4th ed. D.M. Knipe, P.M. Howley, D.E. Griffin (Eds.).
5. Geisbert TW, Jahrling PB Differentiation of filoviruses by electron microscopy. Virus Res 1995, 39:129.
6. Ryabchikova E, Price BBS Ebola and Marburg Viruses: A View of Infection Using Electron Microscopy 2004, Battelle Press, Columbus, OH.
7. Kiley MP, Bowen ET, Eddy GA, et al. Filoviridae: a taxonomic home for Marburg and Ebola viruses?. Intervirology 1982, 18:24.
8. Feldmann H, Muhlberger E, Randolf A, et al. Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle. Virus Res 1992, 24:1.
9. Sanchez A, Kiley MP, Holloway BP, et al. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res 1993, 29:215.
10. Groseth A, Stroher U, Theriault S, et al. Molecular characterization of an isolate from the 1989/90 epizootic of Ebola virus Reston among macaques imported into the United States. Virus Res 2002, 87:155.
11. Ikegami T, Calaor AB, Miranda ME, et al. Genome structure of Ebola virus subtype Reston: differences among Ebola subtypes. Brief report. Arch Virol 2001, 146:2021.
12. Towner JS, Sealy TK, Khristova ML, et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008, 4:e1000212.
13. Muhlberger E, Lotfering B, Klenk HD, et al. Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J Virol 1998, 72:8756.
14. Volchkov VE, Volchkova VA, Muhlberger E, et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001, 291:1965.
15. Neumann G, Feldmann H, Watanabe S, et al. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol 2002, 76:406.
16. Feldmann H, Kiley MP Classification, structure, and replication of filoviruses. Curr Top Microbiol Immunol 1999, 235:1.
17. Sanchez A, Trappier SG, Mahy BW, et al. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci USA 1996, 93:3602.
18. Volchkov VE Processing of the Ebola virus glycoprotein. Curr Top Microbiol Immunol 1999, 235:35.
19. Volchkov VE, Feldmann H, Volchkova VA, et al. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci USA 1998, 95:5762.
20. Volchkov VE, Volchkova VA, Dolnik O, et al. Polymorphism of filovirus glycoproteins. Adv Virus Res 2005, 64:359.
21. Volchkov VE, Volchkova VA, Slenczka W, et al. Release of viral glycoproteins during Ebola virus infection. Virology 1998, 245:110.
22. Volchkov VE, Volchkova VA, Stroher U, et al. Proteolytic processing of Marburg virus glycoprotein. Virology 2000, 268:1.
23. Volchkov VE, Becker S, Volchkova VA, et al. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 1995, 214:421.
24. Volchkova VA, Klenk HD, Volchkov VE Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology 1999, 265:164.
25. Modrof J, Moritz C, Kolesnikova L, et al. Phosphorylation of Marburg virus VP30 at serines 40 and 42 is critical for its interaction with NP inclusions. Virology 2001, 287:171.
26. Muhlberger E, Weik M, Volchkov VE, et al. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J Virol 1999, 73:2333.
27. Becker S, Rinne C, Hofsass U, et al. Interactions of Marburg virus nucleocapsid proteins. Virology 1998, 249:406.
28. Basler CF, Wang X, Muhlberger E, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 2000, 97:12289.
29. Basler CF, Mikulasova A, Martinez-Sobrido L, et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003, 77:7945.
30. Noda T, Sagara H, Suzuki E, et al. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002, 76:4855.
31. Bavari S, Bosio CM, Wiegand E, et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002, 195:593.
32. Huang Y, Xu L, Sun Y, et al. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell 2002, 10:307.
33. Han Z, Boshra H, Sunyer JO, et al. Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J Virol 2003, 77:1793.
34. Volchkov VE, Chepurnov AA, Volchkova VA, et al. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 2000, 277:147.
35. Reid SP, Leung LW, Hartman AL, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006, 80:5156.
36. Reid SP, Valmas C, Martinez O, et al. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol 2007, 81:13469.
37. Mateo M, Reid SP, Leung LW, et al. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signalling. J Virol 2009.
38. Valmas C, Grosch MN, Schumann M, et al. Marburg virus evades interferon responses by a mechanism distinct from Ebola virus. PLoS Pathog 2010, 6:e1000721.
39. Neumann G, Geisbert TW, Ebihara H, et al. Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J Virol 2007, 81:2995.
40. Jeffers SA, Sanders DA, Sanchez A Covalent modifications of the Ebola virus glycoprotein. J Virol 2002, 76:12463.
41. Sanchez A, Yang ZY, Xu L, et al. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 1998, 72:6442.
42. Dolnik O, Volchkova V, Garten W, et al. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 2004, 23:2175.
43. Geyer H, Will C, Feldmann H, et al. Carbohydrate structure of Marburg virus glycoprotein. Glycobiology 1992, 2:299.
44. Will C, Muhlberger E, Linder D, et al. Marburg virus gene 4 encodes the virion membrane protein, a type I transmembrane glycoprotein. J Virol 1993, 67:1203.
45. Kuhn JH, Radoshitzky SR, Guth AC, et al. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 2006, 281:15951.
46. Manicassamy B, Wang J, Jiang H, et al. Comprehensive analysis of Ebola virus GP1 in viral entry. J Virol 2005, 79:4793.
47. Ruiz-Arguello MB, Goni FM, Pereira FB, et al. Phosphatidylinositol-dependent membrane fusion induced by a putative fusogenic sequence of Ebola virus. J Virol 1998, 72:1775.
48. Ito H, Watanabe S, Sanchez A, et al. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol 1999, 73:8907.
49. Gallaher WR Similar structural models of the transmembrane proteins of Ebola and avian sarcoma viruses. Cell 1996, 85:477.
50. Manicassamy B, Wang J, Rumschlag E, et al. Characterization of Marburg virus glycoprotein in viral entry. Virology 2007, 358:79.
51. Chandran K, Sullivan NJ, Felbor U, et al. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005, 308:1643.
52. Schornberg K, Matsuyama S, Kabsch K, et al. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 2006, 80:4174.
53. Schornberg KL, Shoemaker CJ, Dube D, et al. Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc Natl Acad Sci USA 2009, 106:8003.
54. Kaletsky RL, Francica JR, Agrawal-Gamse C, et al. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 2009, 106:2886.
55. Volchkova VA, Feldmann H, Klenk HD, et al. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 1998, 250:408.
56. Barrientos LG, Martin AM, Rollin PE, et al. Disulfide bond assignment of the Ebola virus secreted glycoprotein SGP. Biochem Biophys Res Commun 2004, 323:696.
57. Falzarano D, Krokhin O, Wahl-Jensen V, et al. Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus. ChemBioChem 2006, 7:1605.
58. Sanchez A, Ksiazek TG, Rollin PE, et al. Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates. J Infect Dis 1999, 179(suppl 1):S164.
59. Hayes CG, Burans JP, Ksiazek TG, et al. Outbreak of fatal illness among captive macaques in the Philippines caused by an Ebola-related filovirus. Am J Trop Med Hyg 1992, 46:664.
60. Barrette RW, Metwally SA, Rowland JM, et al. Discovery of swine as a host for the Reston ebolavirus. Science 2009, 325:204.
61. Conrad JL, Isaacson M, Smith EB, et al. Epidemiologic investigation of Marburg virus disease, Southern Africa, 1975. Am J Trop Med Hyg 1978, 27:1210.
62. Peterson AT, Lash RR, Carroll DS, et al. Geographic potential for outbreaks of Marburg hemorrhagic fever. Am J Trop Med Hyg 2006, 75:9.
63. Leirs H, Mills JN, Krebs JW, et al. Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection. J Infect Dis 1999, 179(suppl 1):S155.
64. Reiter P, Turell M, Coleman R, et al. Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies. J Infect Dis 1999, 179(suppl 1):S148.
65. van der Groen G, Webb PA, Johnson KM, et al. Growth of Lassa and Ebola viruses in different cell lines. Ebola Virus Hemorrhagic Fever 1978, 255. Elsevier, Amsterdam. S.R. Pattyn (Ed.).
66. Swanepoel R, Leman PA, Burt FJ, et al. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 1996, 2:321.
67. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005, 438:575.
68. Swanepoel R, Smit SB, Rollin PE, et al. Studies of reservoir hosts for Marburg virus. Emerg Infect Dis 2007, 13:1847.
69. Biek R, Walsh PD, Leroy EM, et al. Recent common ancestry of Ebola Zaire virus found in a bat reservoir. PLoS Pathog 2006, 2:e90.
70. Towner JS, Pourrut X, Albarino CG, et al. Marburg virus infection detected in a common African bat. PLoS ONE 2007, 2:e764.
71. Bertherat E, Talarmin A, Zeller H [Democratic Republic of the Congo: between civil war and the Marburg virus. International Committee of Technical and Scientific Coordination of the Durba Epidemic. Med Trop (Mars) 1999, 59:201.
72. Colebunders R, Tshomba A, Van Kerkhove MD, et al. Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment. J Infect Dis 2007, 196(suppl 2):S148.
73. WHO Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull WHO 1978, 56(2):247.
74. WHO Ebola haemorrhagic fever in Zaire, 1976. Report of an international commission. Bull WHO 1978, 58(2):271.
75. Dowell SF, Mukunu R, Ksiazek TG, et al. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999, 179(suppl 1):S87.
76. Roels TH, Bloom AS, Buffington J, et al. Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure. J Infect Dis 1999, 179(suppl 1):S92.
77. Khan AS, Tshioko FK, Heymann DL, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999, 179(suppl 1):S76.
78. Peters CJ, Jahrling PB, Khan AS Patients infected with high-hazard viruses: scientific basis for infection control. Arch Virol Suppl 1996, 11:141.
79. Zaki SR, Shieh WJ, Greer PW, et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999, 179(suppl 1):S36.
80. Pokhodiaev VA, Gonchar NI, Pshenichnov VA [An experimental study of the contact transmission of the Marburg virus. Vopr Virusol 1991, 36:506.
81. Jaax NK, Davis KJ, Geisbert TJ, et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996, 120:140.
82. Kalongi Y, Mwanza K, Tshisuaka M, et al. Isolated case of Ebola hemorrhagic fever with mucormycosis complications, Kinshasa, Democratic Republic of the Congo. J Infect Dis 1999, 179(suppl 1):S15.
83. Peters CJ, Sanchez A, Feldmann H, et al. Filoviruses as emerging pathogens. Semin Virol 1994, 5:147.
84. Baron RC, McCormick JB, Zubeir OA Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull WHO 1983, 61:997.
85. Francis DP, Smith DH, Highton RB, et al. Ebola fever in Sudan, 1976: Epidemiological aspects of the disease. Ebola Virus Haemorrhagic Fever 1978, 129. Elsevier, Amsterdam. S. Pattyn (Ed.).
86. Sadek RF, Khan AS, Stevens G, et al. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis 1999, 179(suppl 1):S24.
87. Peters CJ, Johnson ED, Jahrling P Filoviruses. Emerging Viruses 1992, 159. Oxford University Press, Oxford. S.S. Morse (Ed.).
88. DeMarcus TA, Tipple MA, Ostrowski SR US policy for disease control among imported nonhuman primates. J Infect Dis 1999, 179(suppl 1):S281.
89. Rollin PE, Williams RJ, Bressler DS, et al. Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States. J Infect Dis 1999, 179(suppl 1):S108.
90. Ksiazek TG, Rollin PE, Jahrling PB, et al. Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates. J Clin Microbiol 1992, 30:947.
91. Elliott LH, Bauer SP, Perez-Oronoz G, et al. Improved specificity of testing methods for filovirus antibodies. J Virol Methods 1993, 43:85.
92. Ksiazek TG, West CP, Rollin PE, et al. ELISA for the detection of antibodies to Ebola viruses. J Infect Dis 1999, 179(suppl 1):S192.
93. Le Guenno B, Formentry P, Wyers M, et al. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995, 345:1271.
94. Formenty P, Boesch C, Wyers M, et al. Ebola virus outbreak among wild chimpanzees living in a rain forest of Cote d'Ivoire. J Infect Dis 1999, 179(suppl 1):S120.
95. Georges AJ, Leroy EM, Renaut AA, et al. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues. J Infect Dis 1999, 179(suppl 1):S65.
96. Bermejo M, Rodriguez-Teijeiro JD, Illera G, et al. Ebola outbreak killed 5000 gorillas. Science 2006, 314:1564.
97. Leroy EM, Rouquet P, Formenty P, et al. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 2004, 303:387.
98. Walsh PD, Abernethy KA, Bermejo M, et al. Catastrophic ape decline in western equatorial Africa. Nature 2003, 422:611.
99. WHO Outbreak of Ebola haemorrhagic fever, Uganda, August 2000-January 2001. Wkly Epidemiol Rec 2001, 76:41.
100. Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004, 78:4330.
101. Bausch DG, Borchert M, Grein T, et al. Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo. Emerg Infect Dis 2003, 9:1531.
102. Feldmann H, Wahl-Jensen V, Jones SM, et al. Ebola virus ecology: a continuing mystery. Trends Microbiol 2004, 12:433.
103. Peterson AT, Bauer JT, Mills JN Ecologic and geographic distribution of filovirus disease. Emerg Infect Dis 2004, 10:40.
104. Towner JS, Khristova ML, Sealy TK, et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol 2006, 80:6497.
105. Feldmann H Marburg hemorrhagic fever - the forgotten cousin strikes. N Engl J Med 2006, 355:866.
106. Schnittler HJ, Feldmann H Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. Curr Top Microbiol Immunol 1999, 235:175.
107. Feldmann H, Klenk HD Marburg and Ebola viruses. Adv Virus Res 1996, 47:1.
108. Feldmann H, Jones S, Klenk HD, et al. Ebola virus: from discovery to vaccine. Nat Rev Immunol 2003, 3:677.
109. Schnittler HJ, Feldmann H Viral hemorrhagic fever - a vascular disease?. Thromb Haemost 2003, 89:967.
110. Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999, 179(suppl 1):S177.
111. Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999, 179(suppl 1):S28.
112. Kibadi K, Mupapa K, Kuvula K, et al. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis 1999, 179(suppl 1):S13.
113. Nikiforov VV, Turovskii Iu I, Kalinin PP, et al. [A case of a laboratory infection with Marburg fever. Zh Mikrobiol Epidemiol Immunobiol 1994, 104.
114. Martini GA, Schmidt HA [Spermatogenic transmission of the "Marburg virus". (Causes of "Marburg simian disease"). Klin Wochenschr 1968, 46:398.
115. Alsop Z Ebola outbreak in Uganda "atypical", say experts. Lancet 2007, 370:2085.
116. Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 1999, 179(suppl 1):S1.
117. Formenty P, Hatz C, Le Guenno B, et al. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. J Infect Dis 1999, 179(suppl 1):S48.
118. Martini GA, Siegert R Marburg Virus Disease 1971, Springer-Verlag, Berlin.
119. Outbreak news. Ebola Reston in pigs and humans, Philippines. Wkly Epidemiol Rec 2009, 84:49.
120. Ebola Reston virus detected pigs in the Philippines. Euro Surveill 2009, 14(4). pii: 19105.
121. Zaki SR, Peters CJ Viral hemorrhagic fevers. The Pathology of Infectious Diseases 1997, 347. Appleton and Lange, Stamford, CT. D.H. Connor (Ed.).
122. Zaki S, Kilmarx PH Ebola virus hemorrhagic fever. Pathology of Emerging Infections 1997, 299. ASM Press, Washington, DC. C.R. Horsburgh, A.M. Nelson (Eds.).
123. Murphy FA, Simpson DI, Whitfield SG, et al. Marburg virus infection in monkeys. Ultrastructural studies. Lab Invest 1971, 24:279.
124. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003, 163:2347.
125. Geisbert TW, Jahrling PB, Hanes MA, et al. Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J Comp Pathol 1992, 106:137.
126. Bray M, Geisbert TW Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 2005, 37:1560.
127. Schnittler HJ, Feldmann H Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages?. Clin Infect Dis 1998, 27:404.
128. Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003, 163:2371.
129. Davis KJ, Anderson AO, Geisbert TW, et al. Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch Pathol Lab Med 1997, 121:805.
130. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999, 179(suppl 1):S203.
131. Hensley LE, Young HA, Jahrling PB, et al. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002, 80:169.
132. Geisbert TW, Hensley LE, Gibb TR, et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000, 80:171.
133. Rubins KH, Hensley LE, Wahl-Jensen V, et al. The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol 2007, 8:R174.
134. Stroher U, West E, Bugany H, et al. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 2001, 75:11025.
135. Feldmann H, Bugany H, Mahner F, et al. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol 1996, 70:2208.
136. Wahl-Jensen V, Kurz SK, Hazelton PR, et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 2005, 79:2413.
137. Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999, 5:423.
138. Villinger F, Rollin PE, Brar SS, et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 1999, 179(suppl 1):S188.
139. Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000, 355:2210.
140. Baize S, Leroy EM, Georges AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002, 128:163.
141. Vallet B Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction?. Crit Care 2003, 7:130.
142. Wahl-Jensen VM, Afanasieva TA, Seebach J, et al. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 2005, 79:10442.
143. Vestweber D The selectins and their ligands. Curr Top Microbiol Immunol 1993, 184:65.
144. Vestweber D Selectins: cell surface lectins which mediate the binding of leukocytes to endothelial cells. Semin Cell Biol 1992, 3:211.
145. Lenter M, Levinovitz A, Isenmann S, et al. Monospecific and common glycoprotein ligands for E- and P-selectin on myeloid cells. J Cell Biol 1994, 125:471.
146. Bockeler M, Stroher U, Seebach J, et al. Breakdown of paraendothelial barrier function during Marburg virus infection is associated with early tyrosine phosphorylation of platelet endothelial cell adhesion molecule-1. J Infect Dis 2007, 196(suppl 2):S337.
147. Peters CJ, Khan AS Filovirus diseases. Curr Top Microbiol Immunol 1999, 235:85.
148. Towner JS, Sealy TK, Ksiazek TG, et al. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J Infect Dis 2007, 196(suppl 2):S205.
149. McCormick JB, Bauer SP, Elliott LH, et al. Biologic differences between strains of Ebola virus from Zaire and Sudan. J Infect Dis 1983, 147:264.
150. Slenczka WG The Marburg virus outbreak of 1967 and subsequent episodes. Curr Top Microbiol Immunol 1999, 235:49.
151. Maruyama T, Parren PW, Sanchez A, et al. Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis 1999, 179(suppl 1):S235.
152. Parren PW, Geisbert TW, Maruyama T, et al. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002, 76:6408.
153. Wilson JA, Hevey M, Bakken R, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000, 287:1664.
154. Krasnianskii BP, Mikhailov VV, Borisevich IV, et al. [Preparation of hyperimmune horse serum against Ebola virus. Vopr Virusol 1995, 40:138.
155. Jahrling PB, Geisbert J, Swearengen JR, et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 1996, 11:135.
156. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999, 179(suppl 1):S18.
157. Jahrling PB, Geisbert JB, Swearengen JR, et al. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007, 196(suppl 2):S400.
158. Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003, 188:1618.
159. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003, 362:1953.
160. Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007, 196(suppl 2):S390.
161. Groseth A, Hoenen T, Alimonti JB, et al. In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. J Infect Dis 2007, 196(suppl 2):S382.
162. Enterlein S, Warfield KL, Swenson DL, et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 2006, 50:984.
163. Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006, 193:1650.
164. Swenson DL, Warfield KL, Warren TK, et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother 2009, 53:2089.
165. Warfield KL, Swenson DL, Olinger GG, et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006, 2:e1.
166. Aman MJ, Kinch MS, Warfield K, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res 2009, 83:245.
167. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007, 3:e2.
168. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008, 82:5664.
169. Daddario-DiCaprio KM, Geisbert TW, Stroher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006, 367:1399.
170. Mikhailov VV, Borisevich IV, Chernikova NK, et al. [The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever. Vopr Virusol 1994, 39:82.
171. Chupurnov AA, Chernukhin IV, Ternovoi VA, et al. [Attempts to develop a vaccine against Ebola fever. Vopr Virusol 1995, 40:257.
172. Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998, 246:134.
173. Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola virus infection. Nat Med 1998, 4:37.
174. Pushko P, Bray M, Ludwig GV, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000, 19:142.
175. Wilson JA, Bray M, Bakken R, et al. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 2001, 286:384.
176. Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002, 8:503.
177. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004, 78:5458.
178. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003, 100:15889.
179. Geisbert TW, Jahrling PB Towards a vaccine against Ebola virus. Expert Rev Vaccines 2003, 2:777.
180. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003, 424:681.
181. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006, 80:9659.
182. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008, 26:6894.
183. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008, 4:e1000225.
184. Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 2009, 83:7296.
185. Warfield KL, Swenson DL, Olinger GG, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007, 196(suppl 2):S430.
186. Swenson DL, Warfield KL, Larsen T, et al. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 2008, 7:417.